5 citations
,
January 2025 in “Cancers” Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.
October 2025 in “Australasian Journal of Dermatology” Bimekizumab effectively treated a man's chronic beard hair loss.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
Using a combination of AMD3100 and FK506 can speed up and improve wound healing in diabetic rats.
5 citations
,
January 2016 in “Indian dermatology online journal” A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.
9 citations
,
August 2024 in “Journal of Orthopaedic Translation” Strontium zinc silicate may help treat osteoporosis and muscle loss.
29 citations
,
June 2015 in “Kidney International” Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
July 2024 in “Journal of Investigative Dermatology” Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
2 citations
,
February 2025 in “Free Radical Biology and Medicine” Blocking S100A8 can reduce chemotherapy-induced hair loss.
June 2019 in “International journal of dermatology and venereology” A man developed skin issues from cancer medication, which improved with specific treatments.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
19 citations
,
August 2023 in “Journal of Dermatological Treatment” Abrocitinib may effectively treat stubborn alopecia universalis.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
February 2026 in “Toxicology Letters” MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
12 citations
,
February 2018 in “Scientific Reports” Using a drug to activate bone marrow stem cells can help the liver regenerate and function better after major surgery in rats.
November 2018 in “Atlas of genetics and cytogenetics in oncology and haematology” WNT10B is linked to cancer development and affects survival and disease progression in various cancers.
May 2024 in “Reactions weekly” August 2025 in “Skin Appendage Disorders” Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
September 2023 in “International journal of molecular sciences” Targeting lipid metabolism can help treat advanced, resistant cancers.
January 2026 in “Elsevier eBooks” 3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
December 2025 in “JEADV Clinical Practice” These new skin treatments are safer and more effective with minimal side effects.